WAM
NAVB

Warberg Asset Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Warberg Asset Management’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-194,997
Closed -$17.5K – 289
2023
Q3 		$17.5K Buy
+194,997
New +$18.1K ﹤0.01% 159
2023
Q2 		– Sell
-28,026
Closed -$7.29K – 312
2023
Q1 		$7.29K Sell
28,026
-133,224
-83% -$38.9K ﹤0.01% 204
2022
Q4 		$33.9K Buy
+161,250
New +$40.3K 0.01% 161

Other funds holding NAVB

BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

Warberg Asset Management's NAVB Position: Q4 2023 in Review

Warberg Asset Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2023, closing a stake of 194,997 shares — an estimated $17.5K sold.

Warberg Asset Management first reported a position in NAVB in Q4 2022 and held it in 3 quarters. The position peaked at $33.9K in Q4 2022. 4 funds tracked by Wall St. Rank hold NAVB as of Q4 2023.

  • Warberg Asset Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2023 after selling out during the quarter.
  • Warberg Asset Management sold 194,997 Navidea Biopharmaceuticals Inc. shares in Q4 2023, an estimated $17.5K.
  • Warberg Asset Management first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2022 and held it in 3 quarters.
  • Warberg Asset Management's Navidea Biopharmaceuticals Inc. position peaked at $33.9K in Q4 2022.
  • 4 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2023.

Based on Warberg Asset Management's 13F filing for Q4 2023, filed 7 Feb 2024.